Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Philip N. Newsome, Kristine Buchholtz, Kenneth Cusi et al. · New England Journal of Medicine · 2020 · 1.9K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Juan P. Frías, Melanie J. Davies, Julio Rosenstock et al. · New England Journal of Medicine · 2021 · 1.9K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes

Gregory Gaich, Jenny Y. Chien, Haoda Fu et al. · Cell Metabolism · 2013 · 879 citations · Full text

Medicine, Endocrinology, Pharmacology +11

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Stephen A. Harrison, Mustafa R. Bashir, Cynthia D. Guy et al. · The Lancet · 2019 · 765 citations

Medicine, Pharmacology, Pharmacotherapy +9

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

Christopher Sorli, Shin‐ichi Harashima, George Tsoukas et al. · The Lancet Diabetes & Endocrinology · 2017 · 707 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13